Early research (Phase 1)UnknownNCT05296772What this trial is testingPhase 1 First-in-human Study of JS014Who this might be right forNeoplasm MalignantNeoplasm, ExperimentalSolid Tumor, Adult+1 more Anwita Biosciences 60
Early research (Phase 1)Study completedNCT01359982What this trial is testingSafety and Pharmacokinetic Study of RRx-001 in Cancer SubjectsWho this might be right forMalignant Solid TumorLymphomas EpicentRx, Inc. 26
Early research (Phase 1)Study completedNCT00608361What this trial is testingDasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By SurgeryWho this might be right forAdult Acute Lymphoblastic Leukemia in RemissionAdult B Acute Lymphoblastic LeukemiaAdult Hepatocellular Carcinoma+82 more National Cancer Institute (NCI) 80
Early research (Phase 1)Ended earlyNCT02110563What this trial is testingPhase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or LymphomaWho this might be right forSolid TumorsMultiple MyelomaNon-Hodgkins Lymphoma+3 more Dicerna Pharmaceuticals, Inc., a Novo Nordisk company 50
Early research (Phase 1)Study completedNCT02076451What this trial is testingOpen-label Study of DS-8273a to Assess Its Safety and Tolerability, and Assess Its Pharmacokinetic and Pharmacodynamic Properties in Subjects With Advanced Solid Tumors or LymphomasWho this might be right forAdvanced Solid TumorLymphoma Daiichi Sankyo 32
Early research (Phase 1)Ended earlyNCT00359294What this trial is testingA Phase I Study of Zalypsis (PM00104) in Subjects With Advanced Malignant Solid Tumors or LymphomaWho this might be right forSolid TumorsLymphoma PharmaMar 12
Early research (Phase 1)Study completedNCT00323934What this trial is testingStudy of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's LymphomaWho this might be right forTumorsNon Hodgkin's Lymphoma Mirati Therapeutics Inc. 42
Testing effectiveness (Phase 2)Active Not RecruitingNCT03210714What this trial is testingErdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)Who this might be right forAdvanced Malignant Solid NeoplasmRecurrent Childhood EpendymomaRecurrent Childhood Malignant Germ Cell Tumor+29 more National Cancer Institute (NCI) 20
Testing effectiveness (Phase 2)Ended earlyNCT03323398What this trial is testingDose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced MalignanciesWho this might be right forRelapsed/Refractory Solid Tumor Malignancies or LymphomaOvarian Cancer ModernaTX, Inc. 79
Early research (Phase 1)Study completedNCT00060632What this trial is testingSafety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED)Who this might be right forTumorsLymphomaMultiple Myeloma Merck Sharp & Dohme LLC 46
Testing effectiveness (Phase 2)Active Not RecruitingNCT02568267What this trial is testingBasket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)Who this might be right forBreast CancerCholangiocarcinomaColorectal Cancer+13 more Hoffmann-La Roche 534
Early research (Phase 1)Ended earlyNCT04553692What this trial is testingPhase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed CancersWho this might be right forSolid TumorColorectal CancerNon Hodgkin Lymphoma+5 more IGM Biosciences, Inc. 272
Early research (Phase 1)Study completedNCT02253420What this trial is testingCOPANLISIB (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma PatientsWho this might be right forMedical Oncology Bayer 51
Early research (Phase 1)Study completedNCT00876122What this trial is testingGDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or IntolerableWho this might be right forNon-Hodgkin's Lymphoma, Solid Cancers Genentech, Inc. 60
Early research (Phase 1)Ended earlyNCT00096005What this trial is testingTanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or LymphomasWho this might be right forAdult Grade III Lymphomatoid GranulomatosisAIDS-related Peripheral/Systemic LymphomaAnaplastic Large Cell Lymphoma+54 more National Cancer Institute (NCI) 36
Early research (Phase 1)Ended earlyNCT02509039What this trial is testingCC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL)Who this might be right forLymphoma, Non-Hodgkin Celgene 15
Early research (Phase 1)Ended earlyNCT02408861What this trial is testingNivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryWho this might be right forAdvanced Malignant Solid NeoplasmAnal CarcinomaHIV Infection+7 more National Cancer Institute (NCI) 79
Testing effectiveness (Phase 2)Active Not RecruitingNCT04320888What this trial is testingSelpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment TrialWho this might be right forHematopoietic and Lymphatic System NeoplasmRecurrent EpendymomaRecurrent Ewing Sarcoma+35 more National Cancer Institute (NCI) 1
Early research (Phase 1)Ended earlyNCT03249792What this trial is testingStudy of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001)Who this might be right forSolid TumorLymphoma Merck Sharp & Dohme LLC 140
Testing effectiveness (Phase 2)Looking for participantsNCT07302347What this trial is testingPembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)Who this might be right forMalignant NeoplasmCarcinoma, Merkel CellLymphoma Merck Sharp & Dohme LLC 20